Bio Developments News Today

Closed Loop Medicine, a techbio company specializing in personalized drug-plus-software therapies, and Pharmanovia, a global pharmaceutical firm known for rejuvenating established medicines, have initiated their OptiZest study.

Proteins present in the blood may be able to predict a person's risk of developing cancer more than seven years before they are diagnosed with the disease, according to new research.

Oxford BioDynamics (OBD) and King’s College London (KCL) have partnered to use OBD’s EpiSwitch technology to identify patients at risk of rheumatoid arthritis (RA) who can benefit from abatacept treatment.

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, have garnered a lot of attention in the pharma industry and beyond.

Adare Pharma Solutions, a tech driven CDMO specializing in oral dosage forms, has announced expansions of its high potency handling capabilities in the U.S. and Europe.

Bristol Myers Squibb partners with Repertoire Immune Medicines to develop innovative vaccines aimed at treating autoimmune disorders more selectively and effectively

Pfizer's groundbreaking $3.5 million gene therapy for hemophilia B just got FDA approval. Here’s what it means for patients and the future of medicine

With equipment that promises to produce 10 times more therapies, the deal with Cellares is hoped to make BSM's CAR-T ambitions more scalable and affordable

Could SynOx's $75M Phase 3 Trial Be the Next Big Leap in TGCT Treatment?

In a recent interview, Hayley Crowe, head of Ecolab's global life sciences business, shed light on Purolite's latest developments and its significant contributions to the biopharmaceutical industry.